{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T17:37:58Z","timestamp":1767980278398,"version":"3.49.0"},"reference-count":0,"publisher":"AME Publishing Company","issue":"3","content-domain":{"domain":["amegroups.com"],"crossmark-restriction":false},"short-container-title":["Chin Clin Oncol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.21037\/cco-20-12","type":"journal-article","created":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T09:26:46Z","timestamp":1592818006000},"page":"29-29","update-policy":"https:\/\/doi.org\/10.21037\/ame_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The history, present situation, and future directions of neoadjuvant chemotherapy for HER2-negative breast cancer"],"prefix":"10.21037","volume":"9","author":[{"given":"Masahiro","family":"Oikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8611","published-online":{"date-parts":[[2020,6]]},"container-title":["Chinese Clinical Oncology"],"original-title":[],"link":[{"URL":"http:\/\/cco.amegroups.com\/article\/download\/44664\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T09:26:51Z","timestamp":1592818011000},"score":1,"resource":{"primary":{"URL":"http:\/\/cco.amegroups.com\/article\/view\/44664\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,6]]},"published-print":{"date-parts":[[2020,6]]}},"URL":"https:\/\/doi.org\/10.21037\/cco-20-12","relation":{},"ISSN":["2304-3865","2304-3873"],"issn-type":[{"value":"2304-3865","type":"print"},{"value":"2304-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}